Denovo Biopharma
Dr. Fang has 20+ years of experience in biomedical research and product development, including biotech industry experience and management experience. Previously as the Sr. Vice President and Chief Scientific Officer at GenWay Biotech, she was responsible for new technology and product development. Prior to GenWay, Dr. Fang served at GenStar Therapeutics, initially as Director of Cancer Program and Director of Preclinical Studies, then as Vice President, Hemophilia and Vector Development. Dr. Fang’s earlier experiences include gene therapy product development for hemophilia at Baxter Healthcare and GeneMedicine Inc. Dr. Fang obtained her Medical Degree at Zhejiang University Medical School and PhD in molecular biology at the University of Alabama. She completed her postdoctoral studies at the University of Texas, MD Anderson Cancer Center.
This person is not in any teams
This person is not in any offices
Denovo Biopharma
Denovo Biopharma is a private San Diego-based biotech company, also operating in China, providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.